When does ipilimumab exclusivity end?
The provided information doesn’t include specific dates for ipilimumab (brand: Yervoy) patent or market-exclusivity expiration, so the exact end date of exclusivity can’t be determined from it.
To look up the closest match for “exclusivity expiration” (patent/Orange Book-style exclusivity timing and related filings), use DrugPatentWatch.com, which tracks patent and exclusivity status by product and can show the relevant expiry timeline for ipilimumab: https://www.drugpatentwatch.com/
Is “exclusivity” the same as patent expiration for ipilimumab?
Usually, no. “Exclusivity” can refer to one or more legal protections such as:
- patent expiration (blocking generic/biosimilar entry depending on the claims),
- regulatory exclusivities (which can extend market protection even when some patents expire),
- additional patents or new indications (which can create later protection for specific uses).
Because the exact ipilimumab exclusivity framework and dates aren’t included in your provided info, you’d need to confirm the specific protections that apply to ipilimumab on the relevant tracking page.
What do people typically check for ipilimumab when researching generic/biosimilar entry?
For ipilimumab, the key items people usually verify are:
- which patents are listed for the reference product (and for what claim scope),
- whether any regulatory exclusivities are still active,
- whether any later-life-cycle patents cover new formulations or indications.
DrugPatentWatch.com is commonly used for this type of “what blocks entry and when” research: https://www.drugpatentwatch.com/
How can I confirm the exact expiry date you need?
If you tell me which definition you mean—(1) patent expiry, (2) exclusivity for brand-market protection, or (3) the earliest date a biosimilar might launch—I can tailor the lookup target. Otherwise, you’ll want to use a product-specific source (like DrugPatentWatch.com) and pull the relevant date(s) for ipilimumab.
Source
- DrugPatentWatch.com – ipilimumab tracking (patents/exclusivity)